Literature DB >> 18073772

Spared caudal brainstem SERT binding in early Parkinson's disease.

Roger L Albin1, Robert A Koeppe, Nicolaas I Bohnen, Kristine Wernette, Michael A Kilbourn, Kirk A Frey.   

Abstract

Postmortem data indicate loss of serotoninergic neurons in Parkinson's disease (PD). We used the serotonin transporter (SERT) radioligand 3-amino-4-(2-dimethylaminomethyl-phenylsulfaryl)-benzonitril (DASB) and positron emission tomography to examine SERT distribution and changes in early PD subjects. We studied five PD subjects (H&Y 1 to 2.5) and eight normal controls. There is reduced SERT binding in PD. The magnitude of DASB binding reductions was greater in the forebrain than in the brainstem regions. There was no asymmetry of diminished SERT binding. DASB binding in the medulla was relatively spared, inconsistent with the description of early prominent pathologic study in these caudal brainstem nuclei.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18073772     DOI: 10.1038/sj.jcbfm.9600599

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  39 in total

1.  In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease.

Authors:  Julie L Wang; Shunichi Oya; Ajit K Parhi; Brian P Lieberman; Karl Ploessl; Catherine Hou; Hank F Kung
Journal:  Nucl Med Biol       Date:  2010-05       Impact factor: 2.408

Review 2.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

3.  Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter.

Authors:  Karl Strecker; Florian Wegner; Swen Hesse; Georg-Alexander Becker; Marianne Patt; Philipp M Meyer; Donald Lobsien; Johannes Schwarz; Osama Sabri
Journal:  J Neurol       Date:  2010-07-21       Impact factor: 4.849

4.  Risk of sleep-disordered breathing in Parkinson's disease.

Authors:  Wattanachai Chotinaiwattarakul; Praveen Dayalu; Ronald D Chervin; Roger L Albin
Journal:  Sleep Breath       Date:  2010-05-16       Impact factor: 2.816

5.  Is serotonin pathology a good biomarker in vivo for early Parkinson's disease?

Authors:  Celia Painous; Andres Perissinotti; Maria J Martí
Journal:  Ann Transl Med       Date:  2019-12

6.  Basal and Evoked Neurotransmitter Levels in Parkin, DJ-1, PINK1 and LRRK2 Knockout Rat Striatum.

Authors:  Rose B Creed; Liliana Menalled; Bradford Casey; Kuldip D Dave; Holden B Janssens; Isaac Veinbergs; Marieke van der Hart; Arash Rassoulpour; Matthew S Goldberg
Journal:  Neuroscience       Date:  2019-04-25       Impact factor: 3.590

Review 7.  Depression in Parkinson disease--epidemiology, mechanisms and management.

Authors:  Dag Aarsland; Sven Påhlhagen; Clive G Ballard; Uwe Ehrt; Per Svenningsson
Journal:  Nat Rev Neurol       Date:  2011-12-26       Impact factor: 42.937

Review 8.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

9.  Cerebral amyloid deposition and serotoninergic innervation in Parkinson disease.

Authors:  Vikas Kotagal; Nicolaas I Bohnen; Martijn L T M Müller; Robert A Koeppe; Kirk A Frey; Roger L Albin
Journal:  Arch Neurol       Date:  2012-12

10.  Brain serotonin transporter in human methamphetamine users.

Authors:  Stephen J Kish; Paul S Fitzmaurice; Isabelle Boileau; Gregory A Schmunk; Lee-Cyn Ang; Yoshiaki Furukawa; Li-Jan Chang; Dennis J Wickham; Allan Sherwin; Junchao Tong
Journal:  Psychopharmacology (Berl)       Date:  2008-10-08       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.